Emergent BioSolutions (EBS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Emergent BioSolutions (EBS) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Emergent BioSolutions (EBS) has a market capitalization of approximately
Emergent BioSolutions's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Emergent BioSolutions runs a net profit margin of -1.3%, a gross margin of 44.4%, and an operating margin of 10.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Emergent BioSolutions reported revenue of $743M for fiscal year 2025, with net income of $53M and earnings per share (EPS) of 0.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Emergent BioSolutions does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Emergent BioSolutions carries a debt-to-equity ratio of 1.10x and a current ratio of 4.29x, with a market beta of 2.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Emergent BioSolutions (EBS) the key facts are: market cap
Get Emergent BioSolutions's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.